Global Artificial Intelligence (AI) in Drug Discovery

Visiongain has published a new report entitled the Artificial Intelligence (AI) in Drug Discovery 2022-2032. It includes profiles of Artificial Intelligence (AI) in Drug Discovery and Forecasts Market Segment by Offering, (AI Software, AI Services) Market Segment by Technology, (Deep Learning, Supervised Learning, Reinforcement Learning, Unsupervised Learning, Other Technology) Market Segment by Applications, (Oncology, Infectious Diseases, Neurological Disorders, Metabolic Diseases, Cardiovascular Diseases, Other Applications) Market Segment by Type, (Target Identification, Molecule Screening, Drug Design and Drug Optimization, Preclinical and Clinical Testing) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) Profiles of Leading Companies, Region and Country.

The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.

In a Pharmacological Screen, AI Has a Stronger Prediction Power for Defining Relevant Interactions

AI makes use of the most recent developments in biology and computation to create cutting-edge drug discovery algorithms. AI has the potential to level the playing field in drug research, with to rapid increases in computing capacity and lower processing costs. In a pharmacological screen, AI has a stronger prediction power for defining relevant interactions. As a result, by carefully choosing the assay parameters in question, the risk of false positives can be decreased. Most crucially, AI has the ability to shift drug screening from the bench to a virtual lab, where results can be produced more quickly and intriguing targets can be prioritised without requiring extensive experimental input or personnel hours.

Download Exclusive Sample of Report @

https://www.visiongain.com/report/ai-drug-discovery-market-2022/#download_sampe_div

How has COVID-19 had…